Longitudinal FEV1 and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 101-111
- https://doi.org/10.2147/copd.s284720
Abstract
Background: Lung function, measured as forced expiratory volume in one second (FEV1), and exacerbations are two endpoints evaluated in chronic obstructive pulmonary disease (COPD) clinical trials. Joint analysis of these endpoints could potentially increase statistical power and enable assessment of efficacy in shorter and smaller clinical trials. Objective: To evaluate joint modelling as a tool for analyzing treatment effects in COPD clinical trials by quantifying the association between longitudinal improvements in FEV1 and exacerbation risk reduction. Methods: A joint model of longitudinal FEV1 and exacerbation risk was developed based on patient-level data from a Phase III clinical study in moderate-to-severe COPD (1740 patients), evaluating efficacy of fixed-dose combinations of a long-acting bronchodilator, formoterol, and an inhaled corticosteroid, budesonide. Two additional studies (1604 and 1042 patients) were used for external model validation and parameter re-estimation. Results: A significant (p< 0.0001) association between FEV1 and exacerbation risk was estimated, with an approximate 10% reduction in exacerbation risk per 100 mL improvement in FEV1, consistent across trials and treatment arms. The risk reduction associated with improvements in FEV1 was relatively small compared to the overall exacerbation risk reduction for treatment arms including budesonide (10– 15% per 160 μg budesonide). High baseline breathlessness score and previous history of exacerbations also influenced the risk of exacerbation. Conclusion: Joint modelling can be used to co-analyze longitudinal FEV1 and exacerbation data in COPD clinical trials. The association between the endpoints was consistent and appeared unrelated to treatment mechanism, suggesting that improved lung function is indicative of an exacerbation risk reduction. The risk reduction associated with improved FEV1 was, however, generally small and no major impact on exacerbation trial design can be expected based on FEV1 alone. Further exploration with other longitudinal endpoints should be considered to further evaluate the use of joint modelling in analyzing COPD clinical trials.This publication has 19 references indexed in Scilit:
- Differential dropout and bias in randomised controlled trials: when it matters and when it may notBMJ, 2013
- Joint modeling of longitudinal and event time data: application to HIV studyJournal of Medical Statistics and Informatics, 2013
- Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized studyRespiratory Medicine, 2012
- Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespiratory Research, 2011
- Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH studyThe Clinical Respiratory Journal, 2010
- Association between lung function and exacerbation frequency in patients with COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2010
- Basic Concepts and Methods for Joint Models of Longitudinal and Survival DataJournal of Clinical Oncology, 2010
- Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary DiseaseDrugs, 2009
- Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseDrugs, 2008
- Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax, 2002